Brief: Synaptogenix Advances Dosing Of Patient In Dose Optimization Clinical Trial In Preparation For Phase 2 Alzheimer's Trial Data

TAO Synergies

20/07/2022 14:26

July 20 (Reuters) - Synaptogenix Inc  SNPX.O :
    * SYNAPTOGENIX ADVANCES DOSING OF FIRST PATIENT IN DOSE
OPTIMIZATION CLINICAL TRIAL IN PREPARATION FOR NIH-SPONSORED,
PHASE 2 ALZHEIMER'S DISEASE TRIAL DATA
    * SYNAPTOGENIX INC - EXPECTS TO ANNOUNCE TOPLINE DATA FROM
ITS NIH
SPONSORED PHASE 2 CLINICAL STUDY DURING Q4 OF 2022
    * SYNAPTOGENIX INC - DOSE OPTIMIZATION PREPARES COMPANY FOR
ITS
NEXT PHASE OF BRYOSTATIN CLINICAL DEVELOPMENT

Source text for Eikon:  ID:nPn22rhJJa 
Further company coverage:  SNPX.O 

 ((Reuters.Briefs@thomsonreuters.com;))